The 2026 Digital Learning Journey in Growth Disorders:
Digital Health and Technologies for Better Patient Outcomes

Thursday **8 October 2026**
From 13:30 to 14:30 CEST

SCIENTIFIC SEMINARS
INTERNATIONAL FOUNDATION

LIVE WEBINAR

Tackling adherence problems in patients with GHD

Con el Aval Científico
de la FSEEP

FUNDACIÓN SEEP

For registration
CLICK HERE

REGISTRATION IS FREE OF CHARGE

OVERVIEW

Adherence to Growth Hormone (GH) therapy has been recognized as an important issue in patients with Growth Hormone Deficiency (GHD). Poor adherence is correlated with reduced catch-up growth in children and with adverse metabolic outcomes in patients transitioning to adult life

LEARNING OBJECTIVES

- Improve knowledge on adherence to GH treatment
- Identify patients with poor adherence
- Improve the use of digital technology to increase adherence
- Learn how to use patient support programs and AI

TARGET AUDIENCE

Paediatricians, Endocrinologists, Paediatric Endocrinologists

LANGUAGE

English with simultaneous translation into Korean and Spanish

CONTINUING MEDICAL EDUCATION

An application has been made to the EACCME® for CME accreditation of the Case-Based Live Webinar **"Tackling adherence problems in patients with GHD"** to be held on 8th October 2026.

CME PROVIDER

Scientific Seminars International Foundation
Senior Programme Manager: Annamaria Nesticò
annamaria.nestico@scientificseminars.com
education@scientificseminars.com

MEDICAL ADVISOR

Sandro Loche
Bambino Gesù Children Hospital, IRCCS
Rome, Italy

FACULTY

Antonio de Arriba Muñoz
Paediatric Endocrinology Unit
Hospital Universitario Infantil “Miguel Servet”
University of Zaragoza
Zaragoza, Spain

Paul Dimitri
Paediatric Endocrinology
Sheffield Children’s NHS Foundation Trust
Sheffield, UK

Sandro Loche
Bambino Gesù Children Hospital, IRCCS
Rome, Italy

TACKLING ADHERENCE PROBLEMS IN PATIENTS WITH GHD

THURSDAY, 8 OCTOBER 2026
From 13:30 to 14:30 CEST

Chair:	S. Loche (Italy)
13.30	**Welcome and introduction** S. Loche (Italy)
13.35	**L1 Adherence to GH therapy: current knowledge** S. Loche (Italy)
13.50	**L2 Patient support programs to improve adherence in GHD** A. de Arriba Muñoz (Spain)
14.05	**L3 Use of AI in pediatric endocrinology** P. Dimitri (UK)
14.20	**Q&A, General Interactive Discussion with participants** Moderator: S. Loche (Italy)
14.30	**Closing remarks and end of the live webinar** S. Loche (Italy)

Con el Aval Científico
de la FSEEP

FUNDACIÓN SEEP

LEGEND

Lecture | Q&A General discussion with participants | Concluding remarks

FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).
We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Antonio de Arriba Muñoz	Declared receipt of honoraria or consultation fees from Merck, Pfizer, Novo Nordisk and Sandoz
Sandro Loche	Declared receipt of honoraria or consultation fees from Merck and Sandoz
Paul Dimitri	Declared receipt of honoraria or consultation fees from Merck

SANDRO LOCHE

Sandro Loche is former Head of the Pediatric Endocrinology Unit at the Pediatric Hospital Microcitemico in Cagliari (Italy). He received his medical degree at the University of Cagliari in 1979, training in Pediatrics and Endocrinology at the University of Cagliari and in Pediatric Endocrinology at the Cornell University Medical College, New York. His main areas of scientific interest include growth and growth disorders, neuroendocrine regulation of GH secretion, diagnosis and treatment of GH deficiency, childhood obesity. He has published over 200 articles, reviews and books. He has served as Editor of the Journal of Endocrinological Investigation and is currently associate editor of Frontiers in Endocrinology.
He received the 2015 Cacciari Prize of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED) for excellence in Pediatric Endocrinology. Sandro Loche is a member of many national and international pediatric and endocrine societies including the American Endocrine Society and the European Society for Pediatric Endocrinology and has served in many societies' committees over the years. He has been an invited speaker to numerous national and international meetings. He is currently a senior researcher at the Bambino Gesù Children Hospital. IRCCS, Rome, Italy.

ANTONIO DE ARRIBA MUÑOZ

Antonio de Arriba Muñoz is a paediatrician specialising in paediatric endocrinology who has focused his research on issues of adherence to growth hormone treatment and the use of new technologies for chronic endocrine diseases. He holds a PhD from the University of Zaragoza and works at the Miguel Servet University Hospital in Zaragoza, Spain.

He has authored over 50 impact-factor publications, focusing on growth hormone therapy adherence and the application of new technologies in paediatric care.

PAUL DIMITRI

Professor Paul Dimitri is a Consultant in Paediatric Endocrinology at Sheffield Children's NHS Foundation Trust. He is Professor of Child Health Technology at the University of Sheffield and Professor of Child Health at Sheffield Hallam University. Professor Dimitri is the Director of the National Institute for Health and Care Research (NIHR) HealthTech Research Centre in Paediatrics and Child Health (https://hrc-children.nihr.ac.uk), and the Clinical Director for the National Technology Innovation Transforming Child Health (TITCH) Network (www.titch.org.uk). He was the previous Director of the NIHR Children & Young People MedTech Cooperative (NIHR CYP MedTech), the UK's first paediatric NIHR MedTech Co-operative. He is the Vice President for Science and Research at the Royal College of Paediatrics and Child Health shaping the national research agenda and policy for child health across the UK through strategic partnerships. He was the NIHR National Children's Specialty Lead from 2016-2024 leading 15 networks to position the UK as a global leader in child health research. Professor Dimitri is leading on the development of the £24.4 million National Centre for Child Health Technology, a global first 42,000 ft2 centre bringing together industry, universities, healthcare professionals, children and young people and their families to develop the most advanced healthcare technologies for children worldwide. Paul has led on the development and implementation of national technology networks that specifically focus on the development and deployment of technology for paediatrics and child health through private and public sector collaboration. These networks have leveraged over £55 million and supported around 200 projects to support the development of child health technology over the last decade. For his achievements, Paul was awarded NIHR Senior Investigator status in 2025. NIHR Senior Investigator status is a prestigious national award recognising the UK's leading researchers in applied health and care. Through a sustained focus on research, innovation, and technology, Professor Dimitri is committed to transforming the health and healthcare of children and young people ensuring that the delivery of meaningful, equitable, and lasting impact.

All Scientific Seminars International Foundation programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This independent educational programme is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt, Germany.

For registration
CLICK HERE

Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com